CytomX Therapeutics (CTMX) EBITDA (2014 - 2026)
CytomX Therapeutics (CTMX) EBITDA from Sep 30, 2014 to Mar 31, 2026. The TTM CytomX Therapeutics (CTMX) EBITDA is -$39M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
CytomX Therapeutics (CTMX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | -3.69% |
| 5 Years TTM | +0.92% |
| 10 Years TTM | +3.82% |
| All Time TTM | +11.11% |
Annual EBITDA change of CytomX Therapeutics (CTMX)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$18M | -14.04% |
| 2025 | -$21M | -179.55% |
| 2024 | $27M | -693.75% |
| 2023 | -$4.48M | -95.48% |
| 2022 | -$99M | -12.70% |
| 2021 | -$113M | +145.54% |
| 2020 | -$46M | -57.38% |
| 2019 | -$108M | +42.64% |
| 2018 | -$76M | +70.34% |
| 2017 | -$45M | -22.89% |
| 2016 | -$58M | +80.78% |
| 2015 | -$32M | +10.42% |
| 2014 | -$29M | +102.66% |
| 2013 | -$14M | N/A |
Comparison CytomX Therapeutics (CTMX) five years EBITDA CAGR with competitors
CytomX Therapeutics (CTMX) five years EBITDA CAGR is -3.20%.